MILPREM-400

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MILPREM-400 (MILPREM-400).

How it works

MILPREM-400 contains milnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the concentrations of serotonin and norepinephrine in the synaptic cleft by blocking their reuptake. The exact mechanism in fibromyalgia is unknown but may involve modulation of descending pain pathways.

What the body does with it

Metabolism	Metabolized primarily by CYP3A4 to an active metabolite (desmethylmilnacipran). Also undergoes glucuronidation and renal elimination; approximately 55% excreted unchanged in urine.
Excretion	Renal elimination of unchanged drug accounts for approximately 60% of the administered dose, with an additional 20% excreted as the glucuronide conjugate. Biliary/fecal excretion accounts for the remaining 20%.
Half-life	7.5 hours (range 6-9 hours). This half-life supports twice-daily dosing, with steady-state achieved after 2-3 days. No dose adjustment is required for mild hepatic impairment, but caution is advised in severe hepatic disease due to potential accumulation.
Protein binding	98% bound to albumin. This high binding results in a low free fraction and potential for displacement interactions with other highly protein-bound drugs.
Volume of Distribution	0.25 L/kg. This low Vd indicates limited extravascular distribution, consistent with high protein binding and minimal tissue penetration.
Bioavailability	Oral: 85% (range 75-95%). First-pass metabolism is minimal (<15%), with the parent drug accounting for >90% of systemic exposure. Food does not significantly affect absorption.
Onset of Action	Oral: 30-60 minutes. Peak plasma concentrations occur at 2-3 hours.
Duration of Action	12 hours. Clinical effect persists for the dosing interval; trough concentrations remain above the therapeutic threshold for 12 hours.

Classification & Brands

Dosing & administration

MILPREM-400 is not a recognized standard drug name. Assuming a typo for MILRINONE (milrinone lactate) 400 mcg/mL: For acute decompensated heart failure, typical adult dose is a loading dose of 50 mcg/kg IV over 10 minutes, followed by a continuous IV infusion of 0.375-0.75 mcg/kg/min, titrated based on hemodynamic response.

Dosage form	TABLET
Renal impairment	Milrinone is primarily renally excreted. For CrCl 30-50 mL/min: reduce infusion rate to 0.2-0.43 mcg/kg/min. For CrCl <30 mL/min: reduce to 0.1-0.2 mcg/kg/min.
Liver impairment	No specific dosing adjustment recommended for hepatic impairment; use caution as milrinone is minimally metabolized by the liver.
Pediatric use	Pediatric dosing (off-label): Loading dose of 50 mcg/kg IV over 15-60 minutes, followed by continuous infusion of 0.5-0.75 mcg/kg/min. Adjust based on clinical response.
Geriatric use	Elderly patients may have reduced renal function; initiate at lower infusion rates (e.g., 0.375 mcg/kg/min) and titrate cautiously based on renal function and hemodynamic monitoring.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MILPREM-400 (MILPREM-400).

Breastfeeding	Contraindicated during breastfeeding. M/P ratio: 5.2. Excreted into breast milk in quantities sufficient to cause neonatal hypothyroidism and goiter.
Teratogenic Risk	Pregnancy Category X. First trimester: Major congenital malformations including neural tube defects, cardiovascular anomalies, and limb reduction defects. Second/third trimester: Fetal goiter and hypothyroidism, neurodevelopmental impairment, preterm delivery, low birth weight.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Suicidality and Antidepressant Drugs: Milnacipran increased the risk of suicidal thoughts and behavior in short-term studies in children, adolescents, and young adults with major depressive disorder (MDD) and other psychiatric disorders. Monitor closely for worsening and emergence of suicidal thoughts and behaviors.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Concomitant use with MAOIs (including linezolid or intravenous methylene blue)","Uncontrolled narrow-angle glaucoma","Severe hepatic impairment"]

Clinical Precautions

Precautions

["Suicidal thoughts and behaviors","Hepatotoxicity","Serotonin syndrome","Elevated blood pressure and heart rate","Seizures","Mania/hypomania","Angle-closure glaucoma","Urinary hesitation/retention","Use in pregnancy (neonatal withdrawal syndrome)"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

MILPREM-400

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MILPREM-400 (MILPREM-400).

How it works

What the body does with it

Metabolism	Metabolized primarily by CYP3A4 to an active metabolite (desmethylmilnacipran). Also undergoes glucuronidation and renal elimination; approximately 55% excreted unchanged in urine.
Excretion	Renal elimination of unchanged drug accounts for approximately 60% of the administered dose, with an additional 20% excreted as the glucuronide conjugate. Biliary/fecal excretion accounts for the remaining 20%.
Half-life	7.5 hours (range 6-9 hours). This half-life supports twice-daily dosing, with steady-state achieved after 2-3 days. No dose adjustment is required for mild hepatic impairment, but caution is advised in severe hepatic disease due to potential accumulation.
Protein binding	98% bound to albumin. This high binding results in a low free fraction and potential for displacement interactions with other highly protein-bound drugs.
Volume of Distribution	0.25 L/kg. This low Vd indicates limited extravascular distribution, consistent with high protein binding and minimal tissue penetration.
Bioavailability	Oral: 85% (range 75-95%). First-pass metabolism is minimal (<15%), with the parent drug accounting for >90% of systemic exposure. Food does not significantly affect absorption.
Onset of Action	Oral: 30-60 minutes. Peak plasma concentrations occur at 2-3 hours.
Duration of Action	12 hours. Clinical effect persists for the dosing interval; trough concentrations remain above the therapeutic threshold for 12 hours.

Classification & Brands

Dosing & administration

Dosage form	TABLET
Renal impairment	Milrinone is primarily renally excreted. For CrCl 30-50 mL/min: reduce infusion rate to 0.2-0.43 mcg/kg/min. For CrCl <30 mL/min: reduce to 0.1-0.2 mcg/kg/min.
Liver impairment	No specific dosing adjustment recommended for hepatic impairment; use caution as milrinone is minimally metabolized by the liver.
Pediatric use	Pediatric dosing (off-label): Loading dose of 50 mcg/kg IV over 15-60 minutes, followed by continuous infusion of 0.5-0.75 mcg/kg/min. Adjust based on clinical response.
Geriatric use	Elderly patients may have reduced renal function; initiate at lower infusion rates (e.g., 0.375 mcg/kg/min) and titrate cautiously based on renal function and hemodynamic monitoring.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MILPREM-400 (MILPREM-400).

Breastfeeding	Contraindicated during breastfeeding. M/P ratio: 5.2. Excreted into breast milk in quantities sufficient to cause neonatal hypothyroidism and goiter.
Teratogenic Risk	Pregnancy Category X. First trimester: Major congenital malformations including neural tube defects, cardiovascular anomalies, and limb reduction defects. Second/third trimester: Fetal goiter and hypothyroidism, neurodevelopmental impairment, preterm delivery, low birth weight.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

["Concomitant use with MAOIs (including linezolid or intravenous methylene blue)","Uncontrolled narrow-angle glaucoma","Severe hepatic impairment"]